Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q1 Revenues Slump 15 Percent as Surge in R&D Spending Widens Loss

NEW YORK (GenomeWeb News) — Third Wave Technologies today said first-quarter revenues slumped 15 percent as R&D spending surged 122 percent and net loss widened 34 percent.  
Total receipts for the three months ended March 31 decreased to $6.7 million from $7.9 million year over year.
Revenue from clinical molecular diagnostics products rose 27 percent to $6 million from $4.7 million, but receipts from research products declined 81 percent to $569,000 from $3 million.
Third Wave CEO Kevin Conroy said molecular diagnostic revenue grew “nicely” over the quarter due to “an ongoing increase in our customer base.”
R&D expenses nearly doubled to $5.1 million compared with $2.3 million the previous year.
“We continue to make a significant investment in the clinical trials for our HPV products,” Conroy said, explaining the cause of the ballooning R&D costs.  
Conroy said the trials “continue to progress very well” and said the current R&D investment will “generate significant value for our shareholders.” Conroy did not say when these products may make it to market.
Net loss for the period swelled to $6.3 million from $4.7 million year over year.
Third Wave had around $47.1 million in cash, cash equivalents, and short-term investments as of March 31.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.